Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities

• Published in: Nature communications Vol. 13; no. 1; p. 514
• Main Authors: Cosgrove, Nicola, Varešlija, Damir, Keelan, Stephen, Elangovan, Ashuvinee, Atkinson, Jennifer M., Cocchiglia, Sinéad, Bane, Fiona T., Singh, Vikrant, Furney, Simon, Hu, Chunling, Carter, Jodi M., Hart, Steven N., Yadav, Siddhartha, Goetz, Matthew P., Hill, Arnold D. K., Oesterreich, Steffi, Lee, Adrian V., Couch, Fergus J., Young, Leonie S.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 26.01.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 13/51; 38/39; 45/23; 49/23; 49/91; 631/114/2114; 631/67/1347; 692/4028/67/322; Adult; Brain; Brain cancer; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Brain tumors; Breast; Breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Explants; Female; Gene mapping; Gene Regulatory Networks; Genes, p53 - genetics; Genomic instability; Homologous recombination; Homology; Humanities and Social Sciences; Humans; Metastases; Metastasis; Middle Aged; Mismatch repair; multidisciplinary; Mutation; Neoplasm Metastasis; Neural plasticity; p53 Protein; Patients; Poly(ADP-ribose) polymerase; Poly(ADP-ribose) Polymerase Inhibitors - pharmacology; Science; Science (multidisciplinary); Transcription; Transcriptome; Transcriptomics; Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-022-27987-5

The molecular events and transcriptional plasticity driving brain metastasis in clinically relevant breast tumor subtypes has not been determined. Here we comprehensively dissect genomic, transcriptomic and clinical data in patient-matched longitudinal tumor samples, and unravel distinct transcriptional programs enriched in brain metastasis. We report on subtype specific hub genes and functional processes, central to disease-affected networks in brain metastasis. Importantly, in luminal brain metastases we identify homologous recombination deficiency operative in transcriptomic and genomic data with recurrent breast mutational signatures A, F and K, associated with mismatch repair defects, TP53 mutations and homologous recombination deficiency (HRD) respectively. Utilizing PARP inhibition in patient-derived brain metastatic tumor explants we functionally validate HRD as a key vulnerability. Here, we demonstrate a functionally relevant HRD evident at genomic and transcriptomic levels pointing to genomic instability in breast cancer brain metastasis which is of potential translational significance. The molecular landscape of breast cancer brain metastases (BCBM) is still understudied, especially for different breast cancer subtypes. Here, the authors characterise subtype-specific BCBMs using genomics and transcriptomics and identify homologous recombination deficiency as a key therapeutic vulnerability.